NuPathe (FRA:QNP) Total Long-Term Liabilities : €4.34 Mil (As of Sep. 2013)

NuPathe Inc., a Delaware corporation was incorporated in January 2005. It is a biopharmaceutical company develops and commercializes branded therapeutics for diseases of the central nervous system, including neurological and psychiatric disorders. The Company's lead product, Zecuity (sumatriptan iontophoretic transdermal system), was approved by the FDA on January 17, 2013 for the acute treatment of migraine, with or without aura, in adults. In addition to Zecuity, it has two pipeline product candidates, NP201 for the continuous symptomatic treatment of Parkinson's disease, and NP202 for the long-term treatment of schizophrenia and bipolar disorder use its proprietary LAD biodegradable implant technology. Zecuity is a single-use, battery-powered patch that actively delivers sumatriptan, the prescribed migraine medication in the U.S., through the skin. Zecuity is the first patch approved by the FDA for the acute treatment of migraine. It expects to make Zecuity available by prescription in the fourth quarter of 2013 and is actively seeking partnerships to maximize the commercial potential for Zecuity in the U.S. and territories throughout the world. Zecuity is designed to overcome limitations of current migraine treatments that are related to route of administration and peak plasma concentrations, and in particular, to address the unmet needs of patients who experience migraine-related nausea (MRN) as part of their attacks. Both of its pipeline product candidates, NP201 and NP202, are designed to deliver therapeutic levels of medication over a period of months with a single dose. NP201, for the continuous symptomatic treatment of Parkinson's disease, utilizes ropinirole, an FDA-approved dopamine agonist, and is designed to provide up to two months of continuous delivery. NP202, for the long-term treatment of schizophrenia and bipolar disorder, is designed to help address the long-standing problem of patient noncompliance by providing three months of continuous delivery of risperidone, an FDA-approved atypical antipsychotic. Its major competitors include organizations such as major multinational pharmaceutical companies, established biotechnology companies and specialty pharmaceutical and generic drug companies. Prescription drug products are subject to extensive pre- and post-market regulation by the FDA, including regulations that govern the testing, manufacturing, distribution, safety, efficacy, approval, labeling, storage, record keeping, reporting, advertising and promotion of such products under the FDCA, and its implementing regulations, and by comparable agencies and laws in foreign countries.